Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2011; 32(02): 109-111
DOI: 10.4103/0971-5851.89795
CASE REPORT

An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib

Jovita Martin
Department of Oncology, Sri Ramachandra Medical College, Sri Ramachandra Medical College and Hospital, Porur, India
,
Anita Ramesh
Department of Oncology, Sri Ramachandra Medical College, Sri Ramachandra Medical College and Hospital, Porur, India
,
Lalitha Devadasan
Department of Obstetrics & Gynaecology, Chennai, Tamil Nadu, India
,
Palaniappan,
Jude J Martin
Assistant Director of Trinity and Company, Chennai, Tamil Nadu, India
› Author Affiliations Source of Support Nil.
› Further Information
  PDF Download Permissions and Reprints

Abstract

The concomitant occurrence of pregnancy and chronic myelogenous leukemia is uncommon. We describe the successful management of a 24-year-old woman in the first trimester of her pregnancy with chronic myelogenous leukemia (CML) in the chronic phase, who was on treatment with imatinib, which was stopped by 10 th week of pregnancy. Until, she completed full term of pregnancy she was on hydroxyurea. The use of imatinib did not have adverse effects on the fetus. The patient had a normal vaginal delivery and gave birth to a healthy 2500 g girl at 37 weeks of gestation. We conclude that imatinib in the first trimester of pregnant lady with CML, though has particular concern regarding the potential teratogenic and other adverse effects, has shown evidences of safe conception, pregnancy and delivery in ladies with CML.

Keywords

CML in pregnancy - imatinib in pregnancy - safety of imatinib in pregnancy


Publication History

Article published online:
06 August 2021

© 2011. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Doll DC, Ringenberg S, Yarbro JW. Management of cancer during pregnancy. Arch Intern Med 1988;148:2058-64.
  • 2 Buekers TE, Lallas TA. Chemotherapy in pregnancy. Obstet Gynecol Clin North Am 1998;25:323-9.
  • 3 Zuazu J, Julia A, Sierra J, Valentin MG, Coma A, Sanz MA, et al. Pregnancy outcome in hematologic malignancies. Cancer 1991;67:703-9.
  • 4 Celiloglu M, Altunyurt S, Undar B. Acta Hydroxyurea treatment for chronic myeloid leukemia during pregnancy Obstet Gynecol Scand 2000; 79: 803-804.
  • 5 Ali R, Ozkalemkaº F, Ozkocaman V, Bülbül-Baºkan E, Ozçelik T, Ozan U, et al.. Successful labor in the course of chronic lymphocytic leukemia (CLL) and management of CLL during pregnancy with leukapheresis. Ann Hematol 2004;83:61-3.
  • 6 Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: Biology and therapy. Ann Intern Med 1999;131:207-19.
  • 7 Mughal TI, Goldman JM. Chronic myeloid leukaemia: STI 571 magnifies the therapeutic dilemma. Eur J Cancer 2001;37:561-8.
  • 8 Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 2002;16:1202-3.
  • 9 Goldman JM, Marin D, Olavarria E, Apperley JF. Clinical decisions for chronic myeloid leukemia in the imatinib era. Semin Hematol 2003;40:98-103.
  • 10 Medina J, Kantarjian H, Talpaz M, O′Brien S, Garcia-Manero G, Giles F, et al. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Cancer 2003;98:1905-11.
  • 11 Hensley ML, Ford JM. Imatinib treatment: Specific issues related to safety, fertility and pregnancy. Semin Hematol 2003;40:21-5.